Fresenius schedules November 4 results. Fresenius stock stands at EUR 24.6 billion market value

Published on 10/15/2026 at 11:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached EUR 5.864 billion, up 6.00 percent year over year. Fresenius stock costs EUR 43.79 on October 15, 2026 versus EUR 43.56.

Results and operating figures

Fresenius completed the remaining mAbxience purchase for up to EUR 750 million on September 30, 2026.
Second-quarter revenue reached EUR 5.864 billion, up 6.00 percent year over year.
Fresenius stock traded at EUR 43.79 at 11:16 a.m. CEST at Lang & Schwarz on October 15, 2026, 0.53 percent above the Xetra close of October 14, 2026.
Fresenius is scheduled to publish third-quarter 2026 results on November 4, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) stock was trading at EUR 43.79 at Lang & Schwarz on October 15, 2026 at 11:16 a.m. CEST, up 0.53 percent versus the Xetra close of October 14, 2026 at EUR 43.56. The company has scheduled its third-quarter 2026 results for November 4, 2026, after publishing its Q3 Aide Memoire on October 13, 2026, according to MarketScreener.

Second-quarter growth sets the baseline

Fresenius reported second-quarter revenue of EUR 5.864 billion, a 6.00 percent increase from EUR 5.571 billion a year earlier. The company also reported EBIT of EUR 719 million, up 10.00 percent from EUR 654 million, while core net income rose 14.00 percent to EUR 470 million from EUR 412 million, according to Fresenius.

The figures were reported before special items, and the company said the core earnings figures excluded Fresenius Medical Care and Vitrea. Fresenius Kabi generated EUR 2.244 billion of revenue, up 7.00 percent, while Helios contributed EUR 3.526 billion, up 5.00 percent, in the second quarter, according to Fresenius.

What does the acquisition mean?

The latest transaction gives Fresenius full ownership of mAbxience, a biosimilars platform with four products on the market and eight development candidates. Fresenius announced on September 30, 2026, that it had acquired the remaining 45 percent for up to EUR 750 million, including a conditional EUR 50 million payment, according to Fresenius.

Three dated steps shape the story

On September 7, 2026, Fresenius sold 7.8 million Fresenius Medical Care shares for around EUR 300 million. On September 30, 2026, it completed the EUR 750 million mAbxience transaction. On October 13, 2026, it released the Q3 Aide Memoire ahead of the November 4, 2026 results date, according to Fresenius.

Dates investors can track

The next scheduled date is November 4, 2026, when Fresenius is due to publish its third-quarter 2026 results. The Q3 Aide Memoire was published on October 13, 2026, providing the immediate company-specific reference point before that report.

Stock value and trading context

Fresenius had a market capitalization of EUR 24.6 billion as of October 15, 2026. Its 52-week range was EUR 35.11 to EUR 52.96, placing the current Lang & Schwarz quote above the yearly low and below the yearly high.

Fresenius stock was trading at EUR 43.79 at Lang & Schwarz on October 15, 2026 at 11:16 a.m. CEST, 0.53 percent above the Xetra close of October 14, 2026 at EUR 43.56. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.